What Is Aspire Biopharma Holdings, Inc. (ASBP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aspire Biopharma Holdings, Inc.'s intrinsic value is estimated at $5.48. Trading at its current price of $6.04, the valuation engine raises significant caution: 7 of 9 models flag downside risk, projecting an average implied return of -9.4%. The most optimistic model, FTNN, places fair value at $15.78 (+161.3%), while ML-RIV — the most conservative — estimates $0.01 (-99.8%). This +261.2% gap reflects genuine analytical uncertainty about Aspire Biopharma Holdings, Inc.'s intrinsic worth.
What Do the Models Say About ASBP?
9 of 13 models are currently active for ASBP. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates ASBP's intrinsic value at $5.10, implying -15.6% downside from the current price. See which stocks rank higher →
How Does ASBP Rank in Biotechnology?
Among 76 Biotechnology stocks, ASBP ranks #43 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
Aspire Biopharma Holdings, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.
Is ASBP a Value Trap?
CirclFi's Value Trap algorithm assigns ASBP a score of 22/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Aspire Biopharma Holdings, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Aspire Biopharma Holdings, Inc. earns a quality score of 4.8/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +261.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ASBP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ASBP's 9 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad